Nội dung được dịch bởi AI, chỉ mang tính chất tham khảo
Mối liên hệ giữa hút thuốc và đi bộ, mệt mỏi, trầm cảm và chất lượng cuộc sống liên quan đến sức khỏe ở bệnh nhân đa xơ cứng
Tóm tắt
Hút thuốc có liên quan đến việc tăng nguy cơ mắc bệnh đa xơ cứng (MS). Ngoài ra, một số nghiên cứu đã báo cáo rằng hút thuốc có liên quan đến lo âu và trầm cảm. Tuy nhiên, cần phải điều tra mối liên hệ giữa hút thuốc, đi bộ và mệt mỏi. Mục tiêu là điều tra mối liên hệ giữa việc hút thuốc lá và đi bộ, mệt mỏi, mức độ nghiêm trọng triệu chứng trầm cảm và chất lượng cuộc sống liên quan đến sức khỏe ở những người mắc MS. Hai trăm bảy mươi chín người bệnh MS đã được đánh giá trong nghiên cứu cắt ngang này. Các kết quả nghiên cứu được đánh giá bao gồm mức độ tàn tật thần kinh, tốc độ đi bộ, sức bền khi đi bộ, tác động cảm nhận về đi bộ của MS, mức độ mệt mỏi, mức độ nghiêm trọng triệu chứng trầm cảm và chất lượng cuộc sống liên quan đến sức khỏe. Có 95 người (34,1%) đang hút thuốc hiện tại có mức độ mệt mỏi (p = 0.003, pη2 = 0.031) và mức độ trầm cảm (p = 0.044, pη2 = 0.015) cao hơn đáng kể, và chất lượng cuộc sống liên quan đến sức khỏe thấp hơn (p = 0.003, pη2 = 0.031) sau khi điều chỉnh theo tuổi, giới tính, mức độ tàn tật thần kinh và thời gian bệnh so với những người không hút thuốc (n = 184). Không có sự khác biệt đáng kể nào giữa những người hút thuốc và không hút thuốc trong các chỉ số đi bộ (p > 0.05). Cường độ hút thuốc có mối tương quan đáng kể với tuổi (r = 0.487), mức độ tàn tật thần kinh (r = 0.227), thời gian bệnh (r = 0.30), tốc độ đi bộ (r = 0.574), sức bền khi đi bộ (r = -0.461), tác động cảm nhận đi bộ của MS (r = 0.684), mệt mỏi (r = 0.370), chất lượng cuộc sống liên quan đến sức khỏe (r = -0.259), và trầm cảm (r = 0.269) ở những người hút thuốc hiện tại. Những người hút thuốc lá mắc MS có mức độ mệt mỏi và mức độ nghiêm trọng triệu chứng trầm cảm cao hơn đáng kể và chất lượng cuộc sống liên quan đến sức khỏe thấp hơn so với những người không hút thuốc. Số năm gói thuốc lá tăng có liên quan đến khả năng đi bộ kém hơn và chất lượng cuộc sống liên quan đến sức khỏe kém hơn, cùng với mức độ nghiêm trọng triệu chứng trầm cảm cao hơn và mệt mỏi nhiều hơn.
Từ khóa
#hút thuốc #đa xơ cứng #đi bộ #mệt mỏi #trầm cảm #chất lượng cuộc sống liên quan đến sức khỏeTài liệu tham khảo
Olsson T, Barcellos LF, Alfredsson L (2017) Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat Rev Neurol 13(1):25–36. https://doi.org/10.1038/nrneurol.2016.187
Riise T, Nortvedt MW, Ascherio A (2003) Smoking is a risk factor for multiple sclerosis. Neurology 61(8):1122–1124. https://doi.org/10.1212/01.wnl.0000081305.66687.d2
Poorolajal J, Bahrami M, Karami M, Hooshmand E (2017) Effect of smoking on multiple sclerosis: a meta-analysis. J Public Health 39(2):312–320. https://doi.org/10.1093/pubmed/fdw030
McKay KA, Jahanfar S, Duggan T, Tkachuk S, Tremlett H (2017) Factors associated with onset, relapses or progression in multiple sclerosis: a systematic review. Neurotoxicology 61:189–212. https://doi.org/10.1016/j.neuro.2016.03.020
Abdollahpour I, Nedjat S, Sahraian MA, Mansournia MA, Otahal P, van der Mei I (2017) Waterpipe smoking associated with multiple sclerosis: a population-based incident case-control study. Mult Scler 23(10):1328–1335. https://doi.org/10.1177/1352458516677867
Hedstrom AK, Hillert J, Olsson T, Alfredsson L (2013) Smoking and multiple sclerosis susceptibility. Eur J Epidemiol 28(11):867–874. https://doi.org/10.1007/s10654-013-9853-4
Heydarpour P, Manouchehrinia A, Beiki O, Mousavi SE, Abdolalizadeh A, Lakeh MM, Sahraian MA (2018) Smoking and worsening disability in multiple sclerosis: a meta-analysis. Acta Neurol Scand 138(1):62–69. https://doi.org/10.1111/ane.12916
Manouchehrinia A, Tench CR, Maxted J, Bibani RH, Britton J, Constantinescu CS (2013) Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study. Brain 136(Pt 7):2298–2304. https://doi.org/10.1093/brain/awt139
Pittas F, Ponsonby AL, van der Mei IA, Taylor BV, Blizzard L, Groom P, Ukoumunne OC, Dwyer T (2009) Smoking is associated with progressive disease course and increased progression in clinical disability in a prospective cohort of people with multiple sclerosis. J Neurol 256(4):577–585. https://doi.org/10.1007/s00415-009-0120-2
Hempel S, Graham GD, Fu N, Estrada E, Chen AY, Miake-Lye I, Miles JN, Shanman R, Shekelle PG, Beroes JM, Wallin MT (2017) A systematic review of modifiable risk factors in the progression of multiple sclerosis. Mult Scler 23(4):525–533. https://doi.org/10.1177/1352458517690270
Hernan MA, Jick SS, Logroscino G, Olek MJ, Ascherio A, Jick H (2005) Cigarette smoking and the progression of multiple sclerosis. Brain 128(Pt 6):1461–1465. https://doi.org/10.1093/brain/awh471
Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, Buckle G, Houtchens M, Stazzone L, Moodie J, Berger AM, Duan Y, Bakshi R, Khoury S, Weiner H, Ascherio A (2009) Smoking and disease progression in multiple sclerosis. Arch Neurol 66(7):858–864. https://doi.org/10.1001/archneurol.2009.122
Van-der-Vuurst-de-Vries RM, Mescheriakova JY, Runia TF, Siepman TAM, Wokke BHA, Samijn JPA, Hintzen RQ (2018) Smoking at time of CIS increases the risk of clinically definite multiple sclerosis. J Neurol 265(5):1010–1015. https://doi.org/10.1007/s00415-018-8780-4
Kvistad S, Myhr KM, Holmoy T, Benth JS, Loken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleas F, Midgard R, Pedersen T, Bakke SJ, Torkildsen O (2016) No association of tobacco use and disease activity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 3(4):e260. https://doi.org/10.1212/NXI.0000000000000260
Munger KL, Fitzgerald KC, Freedman MS, Hartung HP, Miller DH, Montalban X, Edan G, Barkhof F, Suarez G, Radue EW, Sandbrink R, Kappos L, Pohl C, Ascherio A (2015) No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 85(19):1694–1701. https://doi.org/10.1212/WNL.0000000000002099
Petersen ER, Sondergaard HB, Laursen JH, Olsson AG, Bornsen L, Soelberg Sorensen P, Sellebjerg F, Bang Oturai A (2019) Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. Mult Scler 25(9):1298–1305. https://doi.org/10.1177/1352458518791753
Petersen ER, Oturai AB, Koch-Henriksen N, Magyari M, Sorensen PS, Sellebjerg F, Sondergaard HB (2018) Smoking affects the interferon beta treatment response in multiple sclerosis. Neurology 90(7):e593–e600. https://doi.org/10.1212/WNL.0000000000004949
Briggs FBS, Yu JC, Davis MF, Jiangyang J, Fu S, Parrotta E, Gunzler DD, Ontaneda D (2019) Multiple sclerosis risk factors contribute to onset heterogeneity. Mult Scler Relat Disord 28:11–16. https://doi.org/10.1016/j.msard.2018.12.007
McKay KA, Tremlett H, Fisk JD, Patten SB, Fiest K, Berrigan L, Marrie RA, Epidemiology CTit, Impact of Comorbidity on Multiple Score (2016) Adverse health behaviours are associated with depression and anxiety in multiple sclerosis: a prospective multisite study. Mult Scler 22(5):685–693. https://doi.org/10.1177/1352458515599073
Jelinek PL, Simpson S Jr, Brown CR, Jelinek GA, Marck CH, De Livera AM, O'Kearney E, Taylor KL, Neate SL, Weiland TJ (2019) Self-reported cognitive function in a large international cohort of people with multiple sclerosis: associations with lifestyle and other factors. Eur J Neurol 26(1):142–154. https://doi.org/10.1111/ene.13784
Ozcan ME, Ince B, Bingol A, Erturk S, Altinoz MA, Karadeli HH, Kocer A, Asil T (2014) Association between smoking and cognitive impairment in multiple sclerosis. Neuropsychiatr Dis Treat 10:1715–1719. https://doi.org/10.2147/Ndt.S68389
Weiland TJ, Hadgkiss EJ, Jelinek GA, Pereira NG, Marck CH, van der Meer DM (2014) The association of alcohol consumption and smoking with quality of life, disability and disease activity in an international sample of people with multiple sclerosis. J Neurol Sci 336(1–2):211–219. https://doi.org/10.1016/j.jns.2013.10.046
Briggs FB, Gunzler DD, Ontaneda D, Marrie RA (2017) Smokers with MS have greater decrements in quality of life and disability than non-smokers. Mult Scler 23(13):1772–1781. https://doi.org/10.1177/1352458516685169
Jawahar R, Oh U, Eaton C, Wright N, Tindle H, Lapane KL (2014) Association between smoking and health outcomes in postmenopausal women living with multiple sclerosis. Mult Scler Int 2014:686045. https://doi.org/10.1155/2014/686045
Briggs FBS, Thompson NR, Conway DS (2019) Prognostic factors of disability in relapsing remitting multiple sclerosis. Mult Scler Relat Disord 30:9–16. https://doi.org/10.1016/j.msard.2019.01.045
Chamot E, Kister I, Cutter GR (2014) Item response theory-based measure of global disability in multiple sclerosis derived from the performance scales and related items. BMC Neurol 14(1):192. https://doi.org/10.1186/s12883-014-0192-1
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS (2011) Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 69(2):292–302. https://doi.org/10.1002/ana.22366
Faul F, Erdfelder E, Lang A-G, Buchner A (2007) G* Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods 39(2):175–191
Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452. https://doi.org/10.1212/wnl.33.11.1444
Kieseier BC, Pozzilli C (2012) Assessing walking disability in multiple sclerosis. Mult Scler 18(7):914–924. https://doi.org/10.1177/1352458512444498
Fischer JS, Rudick RA, Cutter GR, Reingold SC (1999) The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 5(4):244–250. https://doi.org/10.1177/135245859900500409
Goldman MD, Marrie RA, Cohen JA (2008) Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler 14(3):383–390. https://doi.org/10.1177/1352458507082607
Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ (2003) Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 60(1):31–36. https://doi.org/10.1212/wnl.60.1.31
Dib H, Tamam Y, Terzi M, Hobart J (2017) Testing patient-reported outcome measurement equivalence in multinational clinical trials: an exemplar using the 12-item Multiple Sclerosis Walking Scale. Mult Scler J 3(3):2055217317728740. https://doi.org/10.1177/2055217317728740
Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF (1994) Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis 18(Suppl 1):S79–83. https://doi.org/10.1093/clinids/18.supplement_1.s79
Armutlu K, Keser I, Korkmaz N, Akbiyik DI, Sumbuloglu V, Guney Z, Karabudak R (2007) Psychometric study of Turkish version of Fatigue Impact Scale in multiple sclerosis patients. J Neurol Sci 255(1–2):64–68. https://doi.org/10.1016/j.jns.2007.01.073
Beck AT, Epstein N, Brown G, Steer RA (1988) An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 56(6):893–897. https://doi.org/10.1037//0022-006x.56.6.893
Sacco R, Santangelo G, Stamenova S, Bisecco A, Bonavita S, Lavorgna L, Trojano L, D'Ambrosio A, Tedeschi G, Gallo A (2016) Psychometric properties and validity of Beck Depression Inventory II in multiple sclerosis. Eur J Neurol 23(4):744–750. https://doi.org/10.1111/ene.12932
Hisli N (1989) Beck depresyon envanterinin universite ogrencileri icin gecerliligi, guvenilirligi (A reliability and validity study of Beck Depression Inventory in a university student sample). J Psychol 7:3–13
Simeoni M, Auquier P, Fernandez O, Flachenecker P, Stecchi S, Constantinescu C, Idiman E, Boyko A, Beiske A, Vollmer T, Triantafyllou N, O'Connor P, Barak Y, Biermann L, Cristiano E, Atweh S, Patrick D, Robitail S, Ammoury N, Beresniak A, Pelletier J, MusiQol Study Group (2008) Validation of the multiple sclerosis international quality of life questionnaire. Mult Scler 14(2):219–230. https://doi.org/10.1177/1352458507080733
Cohen J (1988) Statistical power analysis for the behavioural sciences. Erlbaum, In Hillsdale
Marrie RA, Cutter G, Tyry T, Campagnolo D, Vollmer T (2009) Smoking status over two years in patients with multiple sclerosis. Neuroepidemiology 32(1):72–79. https://doi.org/10.1159/000170910
Friend KB, Mernoff ST, Block P, Reeve G (2006) Smoking rates and smoking cessation among individuals with multiple sclerosis. Disabil Rehabil 28(18):1135–1141. https://doi.org/10.1080/09638280500533707
Ramanujam R, Hedstrom AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, Hillert J (2015) Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 72(10):1117–1123. https://doi.org/10.1001/jamaneurol.2015.1788
Tanasescu R, Constantinescu CS, Tench CR, Manouchehrinia A (2018) Smoking cessation and the reduction of disability progression in multiple sclerosis: a cohort study. Nicotine Tob Res 20(5):589–595. https://doi.org/10.1093/ntr/ntx084
World Health Organization (2018) Global health observatory data repository. https://apps.who.int/ghodata/. Accessed 13 Nov 2018
Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A (2001) The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 124(Pt 5):962–973. https://doi.org/10.1093/brain/124.5.962
Taylor KL, Simpson S Jr, Jelinek GA, Neate SL, De Livera AM, Brown CR, O'Kearney E, Marck CH, Weiland TJ (2018) Longitudinal associations of modifiable lifestyle factors with positive depression-screen over 2.5-years in an international cohort of people living with multiple sclerosis. Front Psychiatry 9:526–526. https://doi.org/10.3389/fpsyt.2018.00526
Weiland TJ, Jelinek GA, Marck CH, Hadgkiss EJ, van der Meer DM, Pereira NG, Taylor KL (2015) Clinically significant fatigue: prevalence and associated factors in an international sample of adults with multiple sclerosis recruited via the internet. PLoS ONE 10(2):e0115541–e0115541. https://doi.org/10.1371/journal.pone.0115541
Newland P, Flick L, Xian H, Thomas FP (2016) Symptom co-occurrences associated with smoking in individuals with relapsing-remitting multiple sclerosis. Int J MS Care 18(4):163–168. https://doi.org/10.7224/1537-2073.2014-028
Solaro C, Gamberini G, Masuccio FG (2018) Depression in multiple sclerosis: epidemiology, aetiology, diagnosis and treatment. CNS Drugs 32(2):117–133. https://doi.org/10.1007/s40263-018-0489-5
Leong TI, Weiland TJ, Jelinek GA, Simpson S, Brown CR, Neate SL, Taylor KL, O'Kearney E, Milanzi E, De Livera AM (2018) Longitudinal associations of the healthy lifestyle index score with quality of life in people with multiple sclerosis: a prospective cohort study. Front Neurol 9:874. https://doi.org/10.3389/fneur.2018.00874
Conway DS, Thompson NR, Cohen JA (2016) Influence of hypertension, diabetes, hyperlipidemia, and obstructive lung disease on multiple sclerosis disease course. Mult Scler J 23(2):277–285. https://doi.org/10.1177/1352458516650512